Odronextamab (REGN1979): A Comprehensive Clinical and Scientific Monograph on a CD20xCD3 Bispecific Antibody for B-Cell Malignancies

I. Executive Summary

Odronextamab is an investigational, fully human, off-the-shelf bispecific antibody developed by Regeneron Pharmaceuticals, engineered to treat CD20-positive B-cell malignancies.[1] Classified as a Bispecific T-Cell Engager (BiTE), this immunoglobulin G4 (IgG4)-based therapy represents a significant advancement in immuno-oncology. Its core mechanism of action involves simultaneously binding to the CD20 antigen on malignant B-cells and the CD3 complex on T-cells. This dual engagement forms a cytolytic synapse, redirecting the patient's own T-cells to recognize and eliminate cancer cells through potent, targeted cytotoxicity, independent of traditional immune recognition pathways.[3]

In pivotal clinical trials, odronextamab has demonstrated compelling and durable efficacy in heavily pretreated patient populations with B-cell non-Hodgkin's lymphomas (B-NHLs). For patients with relapsed or refractory (R/R) Follicular Lymphoma (FL), odronextamab achieved an objective response rate (ORR) of approximately 80%, with a remarkably high complete response (CR) rate of 73% and a median duration of response exceeding two years.[6] In the more aggressive setting of R/R Diffuse Large B-Cell Lymphoma (DLBCL), the therapy produced an ORR of approximately 52% and a CR rate of 31%, with a median duration of CR of 18 months.[8]

Critically, odronextamab has shown significant activity in a population with a profound unmet medical need: DLBCL patients who have progressed after receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. In this challenging setting, odronextamab monotherapy yielded an ORR of 48%, effectively doubling the historical median overall survival.[10]

The safety profile of odronextamab is characterized as generally manageable. Cytokine Release Syndrome (CRS) is the most common adverse event; however, its severity is effectively mitigated by an optimized, intravenous step-up dosing regimen, resulting in a low incidence of high-grade events. A key differentiating feature is the near-absence of severe neurotoxicity, specifically Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), a significant concern with other T-cell engaging therapies.[6]

The regulatory journey of odronextamab has been multifaceted. In August 2024, it received approval in the European Union under the trade name Ordspono for the treatment of R/R FL and R/R DLBCL.[11] In the United States, its initial Biologics License Application (BLA) received Complete Response Letters from the Food and Drug Administration (FDA) due to procedural issues related to the enrollment status of its confirmatory trials, with no concerns cited regarding the drug's efficacy or safety. The BLA for R/R FL has since been resubmitted and accepted for review.[11]

Looking forward, odronextamab is positioned as a transformative therapy in the B-NHL landscape. Its off-the-shelf availability provides a significant logistical advantage over cellular therapies. The ongoing, extensive Phase 3 OLYMPIA clinical trial program is evaluating its potential as a chemotherapy-free option in earlier lines of treatment for both FL and DLBCL, which could fundamentally alter the standard of care for these malignancies.[11]

II. Scientific Foundation and Pharmacology

2.1 Molecular Profile and Engineering

Odronextamab is a biotech drug, classified as a New Molecular Entity, developed by Regeneron Pharmaceuticals using its proprietary VelociSuite® technologies.[1] It is a fully human, hinge-stabilized immunoglobulin G4 (IgG4)-based bispecific antibody with a molecular weight of approximately 145.5 kDa.[3] A central feature of its design is that it is "Fc-silenced," meaning the Fc region of the IgG4 backbone has been modified to minimize effector functions such as antibody-dependent cellular cytotoxicity (ADCC) that would otherwise be mediated by non-T-cell immune populations like natural killer (NK) cells.[10] This engineered specificity ensures that the primary driver of tumor cell death is the intended mechanism of T-cell-mediated cytotoxicity, which contributes to a more predictable and potentially more manageable safety profile by reducing off-target immune activation.

Attribute	Description
Generic Name	Odronextamab
Trade Name (EU)	Ordspono™
Alternative Names	REGN-1979; REGN1979; CD20xCD3 bispecific antibody - Regeneron
DrugBank ID	DB16684
CAS Number	1801338-64-6
Originator	Regeneron Pharmaceuticals
Drug Class	Antineoplastics; Bispecific antibodies; Immunotherapies; Bispecific T-Cell Engager (BiTE) Antibodies
Molecular Type	Fully human, Fc-silenced, hinge-stabilized IgG4-based bispecific antibody
Molecular Targets	B-lymphocyte antigen CD20 (MS4A1); T-cell surface glycoprotein CD3 epsilon chain (CD3ε)
ATC Code	L01FX34
Data compiled from sources.1

2.2 Dual-Targeting Mechanism of Action

The therapeutic strategy of odronextamab is predicated on its bispecific nature, allowing it to physically link the immune system's cytotoxic T-cells to malignant B-cells.[19] The antibody possesses two distinct antigen-binding domains. One arm targets the CD20 antigen, a transmembrane protein that is highly and consistently expressed on the surface of B-cells throughout most stages of their development and is a well-validated target in B-cell malignancies.[18] The second arm binds to the CD3 epsilon (CD3ε) subunit, a component of the T-cell receptor (TCR) complex present on virtually all cytotoxic T-cells.[3]

By simultaneously engaging both targets, odronextamab acts as a molecular bridge, forcing a malignant B-cell and a T-cell into close proximity to form an artificial immunological synapse.[10] This induced proximity triggers a potent T-cell activation cascade, leading to T-cell proliferation, secretion of pro-inflammatory cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ), and the release of cytotoxic granules containing perforin and granzymes directly toward the cancer cell.[21]

A crucial aspect of this mechanism is that T-cell activation occurs independently of traditional TCR recognition of a specific peptide antigen presented by the Major Histocompatibility Complex (MHC) on the tumor cell.[18] Heavily pre-treated tumors often evade immune surveillance by downregulating MHC expression, rendering them invisible to conventional T-cell responses. By bypassing this requirement, odronextamab can effectively activate T-cells against tumors that have developed this advanced resistance mechanism. The ultimate outcome is potent, specific, and T-cell-mediated lysis of the CD20-expressing B-cell, harnessing the patient's own immune system to eradicate the malignancy.[3]

2.3 Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical pharmacology of odronextamab has been characterized in studies involving over 500 patients with various B-NHLs, demonstrating consistent profiles across different ethnic populations.[23]

Pharmacokinetics (PK): As a large protein therapeutic, odronextamab is administered intravenously and is primarily cleared through proteolytic catabolism into peptides and amino acids, rather than via hepatic or renal pathways.[14] Its pharmacokinetic profile is dose-dependent. During the initial weekly dosing cycles (C2–C4), drug exposure in patients with DLBCL was approximately two-fold higher than in patients with FL. This difference directly corresponds to the two-fold higher dose administered to the DLBCL cohort (160 mg vs. 80 mg), which was determined to be necessary to achieve maximal therapeutic effect in the more aggressive lymphoma subtype.[23]

Pharmacodynamics (PD): Pharmacodynamic assessments in patients confirm the drug's mechanism of action. Following infusion, odronextamab induces rapid, profound, and sustained depletion of circulating B-cells.[3] Concurrently, there is clear evidence of T-cell engagement, marked by early T-cell activation and proliferation. Notably, the magnitude of T-cell expansion was observed to be greater in patients who achieved a clinical response compared to non-responders, providing a direct link between the pharmacodynamic effect and clinical efficacy.[23] The anticipated release of cytokines was also observed, but this effect was transient and primarily confined to the first cycle of treatment, validating the clinical utility of the step-up dosing regimen in mitigating systemic inflammation.[23]

Exposure-Response Relationship: A formal exposure-response analysis provided a robust rationale for the selected dosing regimens. For FL, the probability of achieving a clinical response increased with odronextamab exposure, reaching a plateau corresponding to an 89% response rate at exposures achieved with the 80 mg weekly dose. For DLBCL, the response also correlated with exposure but required the higher 160 mg weekly dose to achieve the maximal observed response of 57%.[23] Critically, this analysis also established a favorable therapeutic index, as it found no association between increasing drug exposure and the risk of any grade or Grade ≥3 treatment-emergent adverse events (TEAEs), including CRS and infections.[23] This decoupling of efficacy from toxicity at the higher end of the therapeutic range provides strong confidence in the safety and predictability of the chosen dosing strategies.

Trial Identifier	Phase	Key Indications Studied	Primary Objective / Status
ELM-1 (NCT02290951)	Phase 1	R/R B-cell malignancies, including a prespecified expansion cohort for DLBCL post-CAR T-cell therapy	To investigate the safety, tolerability, and recommended Phase 2 dose of odronextamab. Ongoing.
ELM-2 (NCT03888105)	Phase 2	R/R FL, R/R DLBCL, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and other B-NHLs	To investigate the efficacy (primary endpoint: ORR) and safety of odronextamab in disease-specific cohorts. Pivotal results supported regulatory submissions. Ongoing.
OLYMPIA-1 (NCT06091254)	Phase 3	Previously untreated (first-line) Grade 1-3a FL	To evaluate the efficacy and safety of odronextamab monotherapy versus standard-of-care chemo-immunotherapy (e.g., R-CHOP). Recruiting.
OLYMPIA-2 (NCT06097364)	Phase 3	Previously untreated (first-line) FL	To evaluate the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy. Recruiting.
OLYMPIA-3 (NCT06091865)	Phase 3	Previously untreated (first-line) DLBCL	To evaluate the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy. Recruiting.
OLYMPIA-4 (NCT06230224)	Phase 3	R/R aggressive B-NHL (including DLBCL) after one prior line of therapy	To evaluate the efficacy and safety of odronextamab versus standard-of-care salvage therapy in the second-line setting. Recruiting.
NCT06149286	Phase 3	R/R FL and Marginal Zone Lymphoma	To evaluate the efficacy and safety of odronextamab plus lenalidomide versus rituximab plus lenalidomide. Recruiting.
Data compiled from sources.10

III. Clinical Efficacy in Relapsed/Refractory Follicular Lymphoma

The clinical development program for odronextamab has established its profound efficacy in patients with R/R FL, a patient population for whom treatment options become progressively less effective with each relapse.

3.1 Pivotal Evidence from the ELM-2 Trial (NCT03888105)

The pivotal evidence for odronextamab in R/R FL comes from a cohort of the multicenter, open-label Phase 2 ELM-2 study.[11] This cohort enrolled 128 adult patients with heavily pretreated, histologically confirmed Grade 1-3a FL. To be eligible, patients must have experienced relapse or become refractory after receiving at least two prior lines of systemic therapy, which had to include both an anti-CD20 monoclonal antibody (like rituximab) and an alkylating agent.[2] This stringent inclusion criteria ensured the study population was representative of a real-world, difficult-to-treat setting where durable responses are challenging to achieve. The treatment regimen for this cohort consisted of intravenous odronextamab administered in 21-day cycles, featuring a step-up dosing schedule in the first cycle, followed by 80 mg weekly for cycles 2 through 4, and then a maintenance phase of 160 mg every two weeks.[24]

3.2 Primary and Secondary Efficacy Endpoints

The primary endpoint of the study, ORR as assessed by an independent central review committee, was met with compelling results. The analysis demonstrated an ORR of 80.0%.[2] The depth of these responses was particularly noteworthy. In an indolent malignancy like FL, achieving a complete remission is a critical determinant of long-term outcome. Odronextamab induced a CR in 73.4% of patients, meaning over 90% of those who responded achieved a complete clearance of detectable disease.[2]

The responses were not only deep but also highly durable. With a median follow-up of approximately 20 months, the median Duration of Response (DoR) was 23 months, and the median Duration of CR was 24 months.[7] This sustained disease control translated into excellent survival outcomes. The median Progression-Free Survival (PFS) for all patients was 21 months, and for those who achieved a CR, it was 28 months. The median Overall Survival (OS) was not reached during the follow-up period, indicating a significant long-term benefit for this heavily pretreated population.[7]

Efficacy Endpoint (R/R Follicular Lymphoma, ELM-2)	Result
Objective Response Rate (ORR)	80%
Complete Response (CR) Rate	73.4%
Median Duration of Response (DoR)	23 months (95% CI: 17 to NE)
Median Duration of Complete Response (DoCR)	24 months (95% CI: 18 to NE)
Median Progression-Free Survival (PFS)	21 months (95% CI: 17 to 28 months)
Median Overall Survival (OS)	Not Reached (95% CI: 32 months to NE)
CI: Confidence Interval; NE: Not Estimable. Data compiled from sources.2

3.3 Patient-Reported Outcomes and Chemotherapy-Free Potential

Beyond objective measures of tumor response, the clinical benefit of odronextamab was supported by patient-reported outcomes. In FL, which is often managed as a chronic disease requiring multiple lines of therapy over many years, maintaining quality of life is a paramount treatment goal. Data from the ELM-2 trial showed that patients treated with odronextamab maintained their overall health-related quality of life and functional status from baseline through 50 weeks of therapy. Furthermore, statistically significant and clinically meaningful improvements were observed in key areas such as fatigue and lymphoma-specific symptoms.[7]

The combination of high efficacy and preserved quality of life positions odronextamab as a highly attractive chemotherapy-free option.[2] For patients who have already endured the cumulative toxicities of multiple rounds of chemotherapy, a treatment that can induce deep, durable remissions without the associated debilitating side effects represents a significant paradigm shift in the management of relapsed disease.

IV. Clinical Efficacy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

In contrast to the indolent nature of FL, DLBCL is an aggressive B-cell malignancy where up to 50% of patients with advanced disease will relapse or become refractory to first-line treatment, facing a poor prognosis.[9] Odronextamab has demonstrated clinically meaningful activity in this challenging setting, including in the particularly difficult-to-treat population of patients who have failed CAR T-cell therapy.

4.1 Pivotal Evidence from the ELM-2 Trial (CAR-T Naive Cohort)

The DLBCL cohort of the pivotal Phase 2 ELM-2 study enrolled adult patients with R/R DLBCL who had progressed after at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylator.[28] This cohort specifically excluded patients with prior CAR T-cell therapy to assess efficacy in a CAR-T naive but otherwise heavily pretreated population. The patient group was characterized by high-risk features, with 57% having primary refractory disease and 56% having a high-intermediate or high-risk International Prognostic Index (IPI) score of ≥3.[28] Based on exposure-response modeling, these patients received a higher dose regimen than the FL cohort: an initial step-up in Cycle 1, followed by 160 mg weekly for cycles 2-4, and maintenance with 320 mg every two weeks.[24]

In an analysis of 127-130 evaluable patients, odronextamab monotherapy produced an ORR of 49-52% and a CR rate of 31%.[6] The responses proved to be durable, with a median DoR of 10 months. For patients who achieved a complete remission, the disease control was even more prolonged, with a median duration of CR of 18 months.[8]

Efficacy Endpoint (R/R DLBCL, CAR-T Naive, ELM-2)	Result
Objective Response Rate (ORR)	52%
Complete Response (CR) Rate	31%
Median Duration of Response (DoR)	10 months (95% CI: 5 to 18 months)
Median Duration of Complete Response (DoCR)	18 months (95% CI: 10 to NE)
CI: Confidence Interval; NE: Not Estimable. Data compiled from sources.6

4.2 Efficacy in High-Risk Subgroups

A key finding from the ELM-2 trial was the robust and consistent activity of odronextamab across various high-risk DLBCL subgroups. Meaningful responses were observed in patients who are notoriously difficult to treat, including those with high IPI scores, those with double-hit or triple-hit lymphoma (characterized by rearrangements of MYC and BCL2 and/or BCL6 genes), and those with DLBCL that had transformed from a prior indolent lymphoma.[9] This broad activity underscores the potency of the T-cell-mediated cytotoxic mechanism against aggressive disease biology.

4.3 A Novel Option After CAR T-Cell Therapy Failure (ELM-1 Post-CAR-T Cohort)

The establishment of a new therapeutic option for patients who progress after CD19-directed CAR T-cell therapy represents a landmark achievement. This patient population has a dismal prognosis, with a historical median OS of only around 5 months, highlighting a critical unmet medical need.[10] The prespecified post-CAR-T expansion cohort of the Phase 1 ELM-1 study was designed to evaluate odronextamab in this setting.[10] The study enrolled 60 heavily pretreated patients, with a median of 3 prior lines of therapy; a majority (71.7%) were refractory to their prior CAR-T therapy, and nearly half (48.3%) had relapsed within 90 days of their CAR-T infusion, indicating highly aggressive and resistant disease.[10]

The efficacy results in this cohort were highly encouraging. With a median follow-up of 16.2 months, odronextamab monotherapy achieved an ORR of 48.3% and a CR rate of 31.7%.[10] The ability to induce responses in nearly half of these patients, for whom effective options are severely limited, is clinically significant. A primary mechanism of resistance to CD19-targeted CAR T-cell therapy is the loss or downregulation of the CD19 antigen on tumor cells.[10] The strong activity of odronextamab, which targets the distinct CD20 antigen, provides a rational and now evidence-based therapeutic sequence to overcome this specific resistance mechanism.

Furthermore, the responses were durable. The median DoR was 14.8 months, and the median duration of CR was not reached.[10] This translated into a meaningful survival benefit, with a median PFS of 4.8 months and a median OS of 10.2 months—effectively doubling the expected survival in this population.[10] For the subset of patients who achieved a CR, the median PFS and OS were not reached, suggesting the potential for long-term, durable disease control.[32]

Interestingly, subgroup analyses revealed that the likelihood of response to odronextamab correlated with the duration of benefit from the prior CAR T-cell therapy. Patients who had a response to CAR-T lasting 6 months or longer had a much higher ORR (>80%) to subsequent odronextamab compared to those who relapsed in under 3 months (ORR 21%).[32] This suggests that the underlying "fitness" of a patient's T-cells, which can be exhausted by prior therapies, may be a critical determinant of success for subsequent T-cell engaging therapies.

The success in the post-CAR-T salvage setting has also prompted investigation into a synergistic role for odronextamab. A Phase 2 clinical trial is now underway to evaluate odronextamab as a "bridging therapy" administered before CAR T-cell infusion. The goal is to control rapidly progressing lymphoma during the 3-4 week CAR-T manufacturing period, thereby reducing tumor burden and ensuring more patients can receive their cellular therapy in an optimal clinical state.[34] This positions odronextamab not merely as a salvage option for CAR-T failure but as a potential partner to improve CAR-T success rates.

Efficacy Endpoint (DLBCL Post-CAR T-Cell Therapy, ELM-1)	Result
Objective Response Rate (ORR)	48.3%
Complete Response (CR) Rate	31.7%
Median Duration of Response (DoR)	14.8 months (95% CI: 3 to NE)
Median Progression-Free Survival (PFS)	4.8 months (95% CI: 2.6 to 5.4 months)
Median Overall Survival (OS)	10.2 months (95% CI: 4.6 to 15.8 months)
CI: Confidence Interval; NE: Not Estimable. Data compiled from sources.10

V. Comprehensive Safety and Tolerability Profile

The safety and tolerability of odronextamab have been extensively evaluated across its clinical development program. The overall profile is considered generally manageable, particularly within the context of the heavily pretreated patient populations studied. The cornerstone of the safety management strategy is an optimized step-up dosing regimen designed to mitigate the primary toxicity associated with T-cell engaging therapies.

5.1 Characterization of Adverse Events

Treatment-emergent adverse events (TEAEs) are common, with nearly all patients in the pivotal trials experiencing at least one event.[28] The most frequently reported TEAEs (affecting more than 20% of patients) across studies include CRS, neutropenia, pyrexia (fever), anemia, infusion-related reactions, and diarrhea.[6] The most common serious adverse events include CRS, pneumonia, COVID-19, and fever.[6] In the ELM-2 DLBCL cohort, treatment-related TEAEs leading to discontinuation occurred in 8% of patients, and treatment-related Grade 5 (fatal) AEs occurred in 4%.[28] These rates must be interpreted in the context of a patient population with advanced, aggressive disease and compromised immune function from multiple prior therapies.

5.2 Cytokine Release Syndrome (CRS): Incidence and Management

CRS is the most common and clinically significant toxicity associated with odronextamab, occurring in approximately 52-57% of patients in pivotal trial cohorts.[2] This systemic inflammatory response is an on-target effect resulting from the massive T-cell activation induced by the drug. However, the clinical viability of odronextamab hinges on the successful management of this toxicity. The central innovation in this regard is the implementation of a carefully designed, intravenous step-up dosing regimen during the first cycle of therapy (e.g., 0.7 mg, 4 mg, 20 mg before the full therapeutic dose), administered along with steroid premedication.[10]

This strategy has proven highly effective at mitigating the risk of severe CRS. While over half of patients experience CRS, the vast majority of these events are low-grade (Grade 1 or 2) and transient, with a median duration of just 2 days.[7] The incidence of severe (Grade ≥3) CRS is very low; for instance, in the FL cohort receiving the optimized regimen, only 1.7% of patients experienced Grade 3 CRS, and in the post-CAR-T DLBCL cohort, no Grade ≥3 CRS events were reported at all.[7] Due to the potential for severe reactions, treatment must be initiated by an experienced healthcare professional in a setting with appropriate medical support to manage CRS if it occurs.[6]

5.3 Neurological and Hematological Toxicities

Neurotoxicity (ICANS): A key differentiating feature of odronextamab's safety profile is the remarkably low incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). This is a severe and potentially life-threatening neurological toxicity that is a significant concern with other T-cell engaging therapies, particularly CAR T-cells.[35] Across multiple key cohorts, including the post-CAR-T population and DLBCL patients receiving the optimized step-up regimen, no cases of ICANS were reported.[9] This favorable neurotoxicity profile represents a major potential competitive advantage, suggesting a wider therapeutic window and a more favorable risk-benefit balance, especially for older or frailer patients.

Hematological Toxicities: As expected with a therapy that potently activates the immune system and targets B-cells, hematological toxicities are common. Neutropenia was reported in 39-48% of patients, with Grade ≥3 neutropenia occurring in up to 32% of patients in some cohorts.[2] Anemia is also frequently observed, affecting 34-42% of patients.[6]

Infections: Given the B-cell aplasia induced by the therapy and the immunocompromised state of the patient population, infections are a notable risk. Grade ≥3 infections occurred in 12-22% of patients across various cohorts.[10] Prophylactic measures and vigilant monitoring for infectious complications are essential components of patient management.

Adverse Event	Any Grade Incidence (%)	Grade ≥3 Incidence (%)
Cytokine Release Syndrome	52 - 57	< 2
Neutropenia	31 - 48	17 - 32
Pyrexia (Fever)	36 - 43	Not specified
Anemia	34 - 42	12 - 13
Infusion-Related Reactions	31	Not specified
Infections (including COVID-19)	31 (COVID-19)	12 - 22
Diarrhea	>20	Not specified
Thrombocytopenia	>20	Not specified
Data presented as ranges compiled from key trial cohorts (FL, DLBCL, Post-CAR-T). Sources:.2

5.4 Risk Management and Patient Monitoring

Regulatory bodies have emphasized the importance of a structured risk management plan. In Europe, the marketing authorization includes a requirement for the company to provide a patient alert card. This card educates patients on the key risks of CRS and neurological toxicity (including ICANS), providing clear instructions on symptoms to watch for and when to seek urgent medical attention.[6] Clinical protocols mandate that treatment be overseen by physicians experienced in cancer therapy, with dose modifications, delays, or permanent discontinuation as necessary to manage severe side effects.[6]

VI. Regulatory and Market Access Landscape

The regulatory pathway for odronextamab has been distinct in Europe and the United States, reflecting different regulatory philosophies and requirements, particularly concerning the accelerated approval pathway for oncology drugs.

6.1 European Medicines Agency (EMA) Approval

Odronextamab achieved a significant regulatory milestone in August 2024 with its approval for medical use in the European Union under the brand name Ordspono.[8] This decision followed a positive recommendation for a conditional marketing authorization from the EMA's Committee for Medicinal Products for Human Use (CHMP) in June 2024.[15] The approved indication covers the treatment of adult patients with either R/R FL or R/R DLBCL who have progressed after two or more lines of systemic therapy.[6] The approval was based on the strength of the efficacy and safety data from the pivotal Phase 2 ELM-2 trial.

6.2 U.S. Food and Drug Administration (FDA) Review Trajectory

The path to approval in the United States has been more complex. After Regeneron submitted a Biologics License Application (BLA) for both R/R FL and R/R DLBCL, the FDA issued two Complete Response Letters (CRLs) in March 2024, declining to approve the applications at that time.[12]

Crucially, the rationale for the CRLs was not related to any deficiencies in the clinical data. The agency explicitly stated there were no issues concerning the drug's efficacy, safety profile, trial design, labeling, or manufacturing processes.[8] Instead, the CRLs were based on a procedural requirement related to the enrollment status of the mandatory confirmatory trials from the OLYMPIA program.[8] This reflects an increasingly stringent enforcement by the FDA of the principle that for an accelerated approval based on single-arm Phase 2 data, the confirmatory Phase 3 trials must be well underway and substantially enrolled to ensure that the clinical benefit can be verified in a timely manner post-approval.

Following the CRLs, Regeneron continued to advance the OLYMPIA program. Subsequently, the company resubmitted the BLA for the R/R FL indication, and in February 2025, the FDA accepted this resubmission for review.[11] A new Prescription Drug User Fee Act (PDUFA) target action date has been set for July 30, 2025.[2] The non-clinical nature of the initial rejection strongly suggests that once the procedural requirements are met, approval is probable.

6.3 Other Regulatory Designations

To facilitate its development and review, odronextamab has received several important regulatory designations. It was granted Orphan Drug Designation by both the EMA and the FDA for the treatment of FL and DLBCL. This status provides incentives for the development of drugs for rare diseases.[1] Additionally, the FDA granted odronextamab Fast Track Designation for both indications, a process designed to expedite the review of therapies that treat serious conditions and fill a significant unmet medical need.[7]

Date	Regulatory Body	Action	Indication
September 2023	FDA	BLA Granted Priority Review	R/R FL and R/R DLBCL
March 2024	FDA	Complete Response Letters (CRLs) Issued	R/R FL and R/R DLBCL
June 2024	EMA (CHMP)	Positive Opinion for Conditional Marketing Authorization	R/R FL and R/R DLBCL
August 2024	EMA	Marketing Authorization Granted (as Ordspono)	R/R FL and R/R DLBCL
February 2025	FDA	BLA Resubmission Accepted for Review	R/R FL
July 30, 2025	FDA	PDUFA Target Action Date	R/R FL
Data compiled from sources.2

VII. Strategic Analysis and Future Outlook

Odronextamab enters a rapidly evolving and increasingly competitive therapeutic landscape for B-cell non-Hodgkin's lymphomas. Its clinical profile, combined with a strategic development program, positions it to play a significant role in both current and future treatment paradigms.

7.1 Positioning in the Evolving Treatment Paradigm

The emergence of T-cell engaging therapies, including bispecific antibodies and CAR T-cell therapies, has revolutionized the management of R/R B-NHLs. Odronextamab's primary strategic advantage is its status as an "off-the-shelf" product. Unlike autologous CAR T-cell therapies, it does not require patient-specific cell collection (leukapheresis) or a multi-week manufacturing process. This immediate availability makes it a more accessible and logistically feasible option, particularly for patients with rapidly progressing disease or those treated in community oncology settings that lack the specialized infrastructure for cellular therapy.[29]

The choice between a bispecific antibody and CAR T-cell therapy involves a complex clinical calculus. Meta-analyses and clinical experience suggest that CAR T-cell therapy may offer a higher potential for curative outcomes in a subset of patients, but this potential efficacy comes with a higher risk of severe toxicities (especially neurotoxicity), significant logistical hurdles, and substantial cost.[36] Odronextamab and other bispecifics offer a compelling alternative with high response rates, a more favorable safety profile (particularly the low rate of ICANS), and greater accessibility, though they typically require ongoing treatment rather than a one-time infusion.[36]

Therefore, the future of lymphoma treatment is unlikely to be a "winner-take-all" scenario. Instead, it will be a sophisticated ecosystem of sequenced and personalized therapies. Odronextamab is well-positioned to thrive in this environment. It can serve as a primary therapy for patients who are ineligible for or wish to avoid the toxicities of CAR T-cell therapy. Its proven efficacy after CAR-T failure establishes a clear role in a sequential treatment strategy.[10] Furthermore, its investigation as a bridging therapy to CAR-T highlights a potential synergistic role, where it can be used to optimize outcomes for other advanced therapies.[34]

7.2 The Future of Odronextamab: The OLYMPIA Program

While securing a position in the R/R setting is a crucial first step, the ultimate impact of odronextamab will likely be defined by its performance in earlier lines of therapy.[2] Regeneron has initiated an ambitious Phase 3 clinical trial program, named OLYMPIA, to establish odronextamab as a foundational treatment for B-NHLs. This program represents a two-pronged strategy: secure a foothold in the refractory market based on the ELM trial data, while aggressively pursuing the larger, more lucrative frontline market with the potential to displace standard chemotherapy.

Key trials in this program include:

• OLYMPIA-1 (NCT06091254): A pivotal trial evaluating odronextamab monotherapy against the standard of care (rituximab plus chemotherapy) in previously untreated, high-risk FL. Early results from the safety lead-in portion of this trial are exceptionally promising, showing a 100% complete response rate in the first 12 evaluable patients, far exceeding historical benchmarks for chemo-immunotherapy.[13]
• OLYMPIA-2 & OLYMPIA-3 (NCT06097364 & NCT06091865): These trials are exploring odronextamab in combination with chemotherapy versus standard chemo-immunotherapy in the first-line setting for FL and DLBCL, respectively.[11]
• OLYMPIA-4 (NCT06230224): This study is designed to move odronextamab into the second-line setting for aggressive B-NHL, comparing it directly against standard-of-care salvage therapy for patients who relapse early or are refractory to first-line treatment.[40]

7.3 Concluding Analysis

Odronextamab has unequivocally demonstrated its profile as a highly active and generally well-tolerated T-cell engaging bispecific antibody. It has produced deep and durable responses in patients with heavily pretreated R/R FL and R/R DLBCL, addressing a significant unmet need. Its efficacy in patients who have progressed after CAR T-cell therapy provides a vital new salvage option and validates the strategy of sequential targeting of different B-cell antigens.

The combination of its off-the-shelf availability and a favorable safety profile, distinguished by a very low rate of severe neurotoxicity, makes it a highly competitive and accessible therapeutic option. While it has achieved regulatory approval in Europe, its path in the United States has been delayed by procedural requirements, though eventual approval appears likely given the strength of the underlying clinical data.

The future trajectory of odronextamab is promising. The outcomes of the comprehensive OLYMPIA Phase 3 program will be determinative. If the remarkable early signals from the frontline FL study are borne out in the larger randomized trial, odronextamab has the potential to become a cornerstone, chemotherapy-free treatment, fundamentally reshaping the standard of care for B-cell non-Hodgkin's lymphomas for years to come.[2]

Works cited

1. Odronextamab - Regeneron Pharmaceuticals - AdisInsight - Springer, accessed September 30, 2025, https://adisinsight.springer.com/drugs/800041646
2. Odronextamab Back In Front of FDA for Approval | ASH Clinical News, accessed September 30, 2025, https://ashpublications.org/ashclinicalnews/news/8597/Odronextamab-Back-In-Front-of-FDA-for-Approval
3. Odronextamab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 30, 2025, https://go.drugbank.com/drugs/DB16684
4. FDA Accepts Odronextamab BLA in Relapsed/Refractory Follicular, accessed September 30, 2025, https://www.targetedonc.com/view/fda-accepts-odronextamab-bla-in-relapsed-refractory-follicular-lymphoma
5. www.targetedonc.com, accessed September 30, 2025, https://www.targetedonc.com/view/fda-accepts-odronextamab-bla-in-relapsed-refractory-follicular-lymphoma#:~:text=Odronextamab's%20Mechanism%20of%20Action,and%20CD3%20on%20T%20cells.&text=The%20agent%20facilitates%20T%2Dcell,and%20eliminate%20malignant%20B%20cells.
6. Ordspono | European Medicines Agency (EMA), accessed September 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/ordspono
7. Latest Odronextamab Data in Relapsed/Refractory Follicular ..., accessed September 30, 2025, https://investor.regeneron.com/news-releases/news-release-details/latest-odronextamab-data-relapsedrefractory-follicular-lymphoma/
8. Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?, accessed September 30, 2025, https://www.targetedonc.com/view/does-odronextamab-show-hope-in-fl-and-dlbcl-despite-regulatory-hurdles-
9. Updated Odronextamab Data from Relapsed/Refractory Diffuse ..., accessed September 30, 2025, https://investor.regeneron.com/news-releases/news-release-details/updated-odronextamab-data-relapsedrefractory-diffuse-large-b/
10. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study | Blood | American Society of Hematology, accessed September 30, 2025, https://ashpublications.org/blood/article/145/14/1498/534869/Odronextamab-monotherapy-in-R-R-DLBCL-after
11. Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma | Regeneron Pharmaceuticals Inc., accessed September 30, 2025, https://investor.regeneron.com/news-releases/news-release-details/odronextamab-bla-accepted-fda-review-treatment/
12. FDA Denies Approval of Odronextamab in DLBCL and Follicular ..., accessed September 30, 2025, https://www.targetedonc.com/view/fda-denies-approval-of-odronextamab-in-dlbcl-and-follicular-lymphoma
13. Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study, accessed September 30, 2025, https://ashpublications.org/blood/article/144/Supplement%201/4411/529980/Odronextamab-Monotherapy-in-Previously-Untreated
14. Odronextamab by Regeneron Pharmaceuticals for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval, accessed September 30, 2025, https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/
15. Odronextamab - Wikipedia, accessed September 30, 2025, https://en.wikipedia.org/wiki/Odronextamab
16. Odronextamab (Anti-CD20 & CD3) CD markers inhibitor | Read Reviews & Product Use Citations - Selleck Chemicals, accessed September 30, 2025, https://www.selleckchem.com/products/odronextamab.html
17. odronextamab | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 30, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=12690
18. Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, accessed September 30, 2025, https://jitc.bmj.com/content/12/3/e008338
19. Odronextamab: A Breakthrough in Cancer Immunotherapy - Farbe Firma, accessed September 30, 2025, https://www.farbefirma.org/post/odronextamab-a-breakthrough-in-cancer-immunotherapy
20. odronextamab (Pending FDA Approval) - Medscape Reference, accessed September 30, 2025, https://reference.medscape.com/drug/odronextamab-4000420
21. What is the mechanism of action of Odronextamab? - Patsnap Synapse, accessed September 30, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-odronextamab
22. Odronextamab | CD20/CD3 Inhibitor - MedchemExpress.com, accessed September 30, 2025, https://www.medchemexpress.com/odronextamab.html
23. Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies | Blood | American Society of Hematology, accessed September 30, 2025, https://ashpublications.org/blood/article/142/Supplement%201/1436/498907/Odronextamab-Monotherapy-for-the-Treatment-of
24. Paper: Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies, accessed September 30, 2025, https://ash.confex.com/ash/2023/webprogram/Paper180675.html
25. Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39147364/
26. FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma - OncLive, accessed September 30, 2025, https://www.onclive.com/view/fda-issues-crl-for-odronextamab-in-relapsed-refractory-follicular-lymphoma
27. Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1). - ASCO Publications, accessed September 30, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS7096
28. P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2 - PMC - PubMed Central, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10431082/
29. Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study, accessed September 30, 2025, https://ashpublications.org/blood/article/142/Supplement%201/4461/500435/Odronextamab-Demonstrates-Durable-Complete
30. Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39786390/
31. ashpublications.org, accessed September 30, 2025, https://ashpublications.org/blood/article/145/14/1498/534869/Odronextamab-monotherapy-in-R-R-DLBCL-after#:~:text=In%20patients%20with%20diffuse%20large,20%25%20grade%20%E2%89%A53%20infections.
32. Odronextamab Shows Efficacy in DLBCL Post CAR T-Cell Therapy | Targeted Oncology, accessed September 30, 2025, https://www.targetedonc.com/view/odronextamab-shows-efficacy-in-dlbcl-post-car-t-cell-therapy
33. Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma | Regeneron Pharmaceuticals Inc., accessed September 30, 2025, https://investor.regeneron.com/news-releases/news-release-details/odronextamab-ash-presentations-underscore-impressive-potential/
34. Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T, accessed September 30, 2025, https://www.fredhutch.org/en/research/clinical-trials/trial-details.fh_trial_id_15368.odronextamab-for-relapsed-and-refractory-large-b-cell-lymphomas-before-car-t.html
35. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma - PMC, accessed September 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12309599/
36. CARs vs bispecifics: the race is on! | Blood - American Society of Hematology, accessed September 30, 2025, https://ashpublications.org/blood/article/144/6/592/517227/CARs-vs-bispecifics-the-race-is-on
37. CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies - CancerNetwork, accessed September 30, 2025, https://www.cancernetwork.com/view/car-t-vs-bispecifics-expanding-car-t-reach-in-b-cell-malignancies
38. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas - PubMed, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/38331870/
39. CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis - Frontiers, accessed September 30, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1611984/full
40. Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4). - ASCO Publications, accessed September 30, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS7093
41. Follicular Lymphoma Treatment: What's the Latest? - Dana-Farber Cancer Institute, accessed September 30, 2025, https://blog.dana-farber.org/insight/2024/04/follicular-lymphoma-treatment-whats-the-latest/
42. Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives, accessed September 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39971627/
43. Odronextamab Recruiting Phase 3 Trials for Relapsed or Refractory Follicular Lymphoma / Marginal Zone Lymphoma (MZL) Treatment - DrugBank, accessed September 30, 2025, https://go.drugbank.com/drugs/DB16684/clinical_trials?conditions=DBCOND0110322%2CDBCOND0071783&phase=3&purpose=treatment&status=recruiting
44. Odronextamab Recruiting Phase 3 Trials for Follicular Lymphoma (FL) Treatment, accessed September 30, 2025, https://go.drugbank.com/drugs/DB16684/clinical_trials?conditions=DBCOND0071151&phase=3&purpose=treatment&status=recruiting
45. Odronextamab Recruiting Phase 3 Trials for B-Cell Non-Hodgkin Lymphoma (NHL) Treatment | DrugBank Online, accessed September 30, 2025, https://go.drugbank.com/drugs/DB16684/clinical_trials?conditions=DBCOND0081845&phase=3&purpose=treatment&status=recruiting